Skip to main content
. 2007 Aug 10;110(9):3143–3149. doi: 10.1182/blood-2007-04-086314

Table 3.

Analysis of data from 19 HIV+ patients used for PBMC and CD34+ cell proviral analysis

Patient no. CD4, count/μL Sex HGB, g/dL PBMC proviral, per 104 cells CD34+ proviral, per 104 cells
1 153 F 11.7 34.8 0.0
2 94 F 13.9 7.3 0.0
3* 50 M 9.8 17.32 1262
4* 104 M 15.6 77.0 5300
5* 94 M 11.3 106 1034
6* 13 F 9.8 3.74 3800
7 44 F 11 78.0 0.0
8 226 F 11.9 47.6 145.4
9 90 F 9.1 45 195.8
10 124 M 14.5 68.4 0.0
11 75 F 11.7 5.14 0.0
12 143 M 14.4 38.6 0.0
13* 113 M 7.7 36.8 354
14 10 F 9.6 146.6 0.0
15 5 M 9 38.6 238
16* 53 M 15.6 116.2 742
17* 54 F 10 66.8 2080
18* 71 F 8.3 101.2 4500
19* 186 F 4.8 142 2200

Samples were collected from HIV-positive patients beginning the national HAART regimen at the Infectious Disease Care Clinic in Gaborone, Botswana. All patients were antiretroviral drug–naive. CD34+ cells were isolated using a magnetic bead positive selection (Invitrogen). Patients with a CD34+ cell proviral load that was significantly higher than their respective PBMC proviral load are indicated *(t test, P < .005, ‡P < .05). Eight of 9 anemic patients (nos. 3, 6, 9, 13, 15, and 17-19) had positive CD34+ cell populations, a significantly higher portion than the 3 of 10 nonanemic patients (nos. 4, 5, and 16; Fisher exact test, P < .05).

Patients who had anemia (HGB ≤ 10 g/dL).